Baijin Life Science Holdings Limited
Baijin Life Science Holdings Limited Fundamental Analysis
Baijin Life Science Holdings Limited (1466.HK) shows weak financial fundamentals with a PE ratio of 60.19, profit margin of 6.75%, and ROE of 5.77%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 43.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1466.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1466.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1466.HK shows balanced valuation metrics.
Growth Score
Moderate1466.HK shows steady but slowing expansion.
Financial Health Score
Excellent1466.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1466.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1466.HK Expensive or Cheap?
P/E Ratio
1466.HK trades at 60.19 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1466.HK's PEG of 0.05 indicates potential undervaluation.
Price to Book
The market values Baijin Life Science Holdings Limited at 3.45 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 43.86 times EBITDA. This signals the market has high growth expectations.
How Well Does 1466.HK Make Money?
Net Profit Margin
For every $100 in sales, Baijin Life Science Holdings Limited keeps $6.75 as profit after all expenses.
Operating Margin
Core operations generate -12.04 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.77 in profit for every $100 of shareholder equity.
ROA
Baijin Life Science Holdings Limited generates $2.87 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Baijin Life Science Holdings Limited generates limited operating cash flow of $-13.23M, signaling weaker underlying cash strength.
Free Cash Flow
Baijin Life Science Holdings Limited generates weak or negative free cash flow of $-15.39M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.02 in free cash annually.
FCF Yield
1466.HK converts -3.15% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
60.19
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.45
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.07
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.61
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.21
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.06
vs 25 benchmark
How 1466.HK Stacks Against Its Sector Peers
| Metric | 1466.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 60.19 | 23.72 | Worse (Expensive) |
| ROE | 5.77% | 1091.00% | Weak |
| Net Margin | 6.75% | -627.00% (disorted) | Weak |
| Debt/Equity | 0.61 | 0.72 | Neutral |
| Current Ratio | 4.21 | 2.64 | Strong Liquidity |
| ROA | 2.87% | 1053.00% | Weak |
1466.HK outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Baijin Life Science Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary
EPS CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary
FCF CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary